Patent · US Active

Multiple exon skipping compositions for DMD

US9234198B1 · kind B1 · utility

32Cited by
79References
8Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 11, 2015
Grant dateJan 12, 2016
Priority date—
Expiry dateSep 11, 2035

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2320/33
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

Provided are antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, and methods of use thereof to treat muscular dystrophy.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.